Latest NeuroSense Therapeutics News & Updates

See the latest news and media coverage for NeuroSense. We track all announcements, press releases, and industry mentions in real time, all in one place.

NeuroSense Therapeutics (NeuroSense)

Clinical-stage biotech developing neurodegenerative disease treatments

neurosense-tx.com

Headquarters: Cambridge, United States
Founded year: 2017
Company type: Public company
Number of employees: 25–50
Industry: Pharmaceuticals

Last updated Today

Latest news about NeuroSense Therapeutics (NeuroSense)

In short: NeuroSense advanced its ALS drug candidate PrimeC toward regulatory submission in Canada and reported positive Phase 2 Alzheimer's data.

Company announcements

July 28 NeuroSense

NeuroSense reports positive Phase 2 biomarker findings in Alzheimer's

The plasma biomarker analysis showed multiple distinctive protein changes, supporting PrimeC's target engagement and building on its previously reported safety profile.

July 22 NeuroSense

NeuroSense advances PrimeC toward Health Canada submission for ALS

The submission follows alignment on NDS pathway and is supported by PARADIGM data showing survival benefit.

June 29 NeuroSense

NeuroSense achieves primary endpoint in Phase 2b ALS study

TDP-43 reduction with statistical significance, supporting PrimeC's disease-modifying potential.

June 25 NeuroSense

NeuroSense reports positive biomarker findings from Phase 2 PrimeC study

The findings show changes in tau, amyloid-beta, and other protein biomarkers, suggesting potential target engagement in Alzheimer's disease.

Media coverage

July 31 The Globe and Mail

NeuroSense Updates Capital on Demand Program After New F-3 Becomes Effective

Detailed price information for Neurosense Therapeutics Ltd (NRSN-Q) from The Globe and Mail including charting and trades.

July 22 Yahoo Finance

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced it intends to proceed...

June 25 The Globe and Mail

NeuroSense's ALS Drug PrimeC Shows Strong Phase 2b Results in JAMA Neurology

Detailed price information for Neurosense Therapeutics Ltd (NRSN-Q) from The Globe and Mail including charting and trades.

June 25 Yahoo Finance

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced positive biomarker findings from its...

Never miss news about NeuroSense

Track NeuroSense and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

NeuroSense competitors & trending companies

Browse news for competitors to NeuroSense and other trending companies.